399: OUTCOMES BY KEY PROGNOSTIC FACTORS IN EMERALD-1: A PHASE 3 STUDY OF DURVALUMAB ± BEVACIZUMAB WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PARTICIPANTS WITH EMBOLIZATIONELIGIBLE UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Nadine Abi‐Jaoudeh, Masatoshi Kudo, Stephen L. Chan, Riccardo Lencioni, Thomas Decaens, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Mohamed Bouattour, Yasuaki Arai, Jeong Heo, В. В. Бредер, Farshid Dayyani, Alejandro Molina Alavez, Joong‐Won Park, Jung‐Hwan Yoon, Kwong‐Ming Kee, Tanita Suttichaimongkol, Yoshitaka Inaba, Rebecca Griffin, Magdalena Żotkiewicz, Claire Morgan, Sajid Ali, Kavitha Balaji, Bruno Sangro
IF 25.1 (2025) Gastroenterology